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Abstract
The infection with Brucella abortus, Brucella melitensis and Brucella suis has been assessed according
to the criteria of the Animal Health Law (AHL), in particular criteria of Article 7 on disease proﬁle and
impacts, Article 5 on the eligibility of the infection with B. abortus, B. melitensis and B. suis to be
listed, Article 9 for the categorisation of the infection with B. abortus, B. melitensis and B. suis
according to disease prevention and control rules as in Annex IV and Article 8 on the list of animal
species related to the infection with B. abortus, B. melitensis and B. suis. The assessment has been
performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, the infection
with B. abortus, B. melitensis and B. suis can be considered eligible to be listed for Union intervention
as laid down in Article 5(3) of the AHL. The disease complies with the criteria as in Sections 2, 3, 4
and 5 of Annex IV of the AHL, for the application of the disease prevention and control rules referred
to in points (b), (c), (d) and (e) of Article 9(1). The animal species to be listed for the infection with
B. abortus, B. melitensis and B. suis according to Article 8(3) criteria are several mammal species, as
indicated in the present opinion.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL)
framework (EFSA AHAW Panel, 2017).
The present document reports the results of assessment on the infection with Brucella abortus,
Brucella melitensis and Brucella suis according to the criteria of the AHL articles as follows:
• Article 7: the infection with B. abortus, B. melitensis and B. suis proﬁle and impacts;
• Article 5: eligibility of the infection with B. abortus, B. melitensis and B. suis to be listed;
• Article 9: categorisation of the infection with B. abortus, B. melitensis and B. suis according to
disease prevention and control rules as in Annex IV;
• Article 8: list of animal species related to the infection with B. abortus, B. melitensis and
B. suis.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of the infection with B. abortus, B. melitensis and B. suis
according to the Article 7 criteria of the AHL and related parameters (see Table 2 of the opinion on
methodology (EFSA AHAW Panel, 2017)), based on the information contained in the fact-sheet as
drafted by the selected disease scientist (see section 2.1 of the scientiﬁc opinion on the ad hoc
methodology) and amended by the EFSA Panel on Animal Health and Welfare (AHAW).
3.1.1. Article 7(a) Disease Proﬁle
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
B. abortus/B. melitensis
Most if not all wild mammals are theoretically susceptible, but ungulates are the most frequently
affected wild animals, usually as a consequence of contact with infected livestock in extensive breeding
systems. Infections have been reported in the one-humped (Camelus dromedarius) and two-humped
(Camelus bactrianus) camels, llama (Lama glama), alpaca (Vicugna pacos), guanaco (Lama guanicoe),
vicu~na (Vicugna vicugna), water buffalo (Bubalus bubalis), European (Bison bonasus) and American
bison (Bison bison), yak (Bos grunniens), African buffalo (Syncerus caffer), red deer (Cervus elaphus),
moose (Alces alces), wild boar (Sus scrofa) and several species of African antelope, such as Kafue
lechwe antelope (Kobus leche kafuensis), Arabian oryx (Oryx leucoryx) and sable antelope
(Hippotragus niger) (Dıaz-Aparicio, 2013; Godfroid et al., 2013). Sporadic cases have been reported
also in carnivores like opossums (family Didelphidae), raccoons (Procyon lotor), coyotes
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(Canis latrans), foxes (Vulpes vulpes) and wolves. In the European Union (EU), brucellosis due to both
bacterial species has been reported only sporadically in wild ungulates such as ibex (Capra ibex),
chamois (Rupicapra sp.), Spanish ibex (Capra pyrenaica) and red deer (Cervus elaphus) (Gortazar
et al., 2007; Mu~noz et al., 2010; Mick et al., 2014). However, these wild animals are considered
occasional end hosts of brucellosis transmitted from infected livestock, rather than a true reservoir of
the disease (Gortazar et al., 2007).
B. suis
This bacterial species is composed by ﬁve biovars (named from 1 to 5), with biovars 1, 2 and 3
causing brucellosis in domestic swine. This complexity accounts for the different types of
epidemiological situations occurring in non-porcine and wild species. B. suis infection can occur in
animals that are not the natural host of the particular infection through the ingestion of contaminated
materials or by cohabitation with infected natural hosts. As examples, arctic foxes (Vulpes lagopus)
and wolves (Canis lupus) may be infected by B. suis biovar 4 after eating infected reindeer. B. suis
biovar 4 is a zoonotic agent and also causes a serious disease in wild or domesticated reindeer or
caribou (Rangifer tarandus and its various subspecies) throughout the Arctic region, including Siberia,
Canada and Alaska. Dogs and rodents, such as rats and mice, may acquire other B. suis biovars by
cohabitation with infected hosts. In some cases, wildlife species are natural hosts for some B. suis
biovars, as it has been reported in the former Soviet Union and the Baltic countries, where small
rodents are infected by B. suis biovar 5 (EFSA, 2009; OIE, 2016). Infection by B. suis biovar 2 (which
is a very rare zoonotic agent, see below) is reported frequently in the EU affecting the Eurasian wild
boar (Sus scrofa) and the European brown hare (Lepus europaeus). Both wild species can transmit the
infection to domestic pigs in outdoor farms, thus playing a relevant role as a reservoir of porcine
brucellosis (EFSA, 2009; Mu~noz et al., 2010). Outside the EU, feral pigs and peccaries (Tayassuidae)
may maintain B. suis biovars 1 and 3 (both are important zoonotic agents) with the ensuing risks for
both pigs and humans. These two last biovars are considered not to exist in the EU, with a unique and
very rare exception reported for biovar 3 in horses in Croatia (Cvetnic et al., 2005), although this strain
was ﬁnally identiﬁed as belonging to the biovar 1 (Fretin et al., 2008).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
B. abortus
Cattle (primarily) and sheep and goats (very rarely). Sporadic cases have been reported also in
farmed water buffalo (Bubalus bubalis) and, even more rarely, in horses and pigs (Cvetnic et al., 2005;
OIE, 2016). Dogs belonging to infected herds are also found infected frequently. Outside the EU, in
addition to the above domestic species, yak (Bos grunniens) and camels (both species) can be also
found infected in mixed breeding systems (OIE, 2016).
B. melitensis
Sheep and goats (primarily) and cattle (less frequently and only when bovines and cattle cohabit
with small ruminants (Verger et al., 1989; OIE, 2016)). Sporadic cases have been reported in farmed
water buffaloes (Bubalus bubalis) and, more rarely, in horses and pigs (Cvetnic et al., 2005; OIE,
2016). Dogs belonging to infected ﬂocks are also found infected frequently. Outside the EU, in addition
to these domestic species, yak (Bos grunniens) and camels (both species) can be also found infected
(OIE, 2016).
B. suis
As indicated above, the biovars 1, 2 and 3 infect domestic swine and are responsible for porcine
brucellosis. B. suis biovar 2 infection is restricted to Continental Europe, and widespread in wildlife (see
above) causing sporadic outbreaks in domestic swine reared in outdoor breeding systems. Very rare
cases of B. suis biovar 2 infection have been reported in cattle, not followed by clinical signs (Fretin
et al., 2013; Szulowski et al., 2013) and horses (Quaranta et al., 1995). B. suis biovars 1 and/or 3 are
widespread in pigs in America, Asia, Oceania and probably Africa, causing also human brucellosis
(unlike biovar 2, both biovars are important zoonotic agents). Infections by these biovars have been
reported also in domestic dogs (Ramamoorthy et al., 2011). Biovar 3 is considered absent from the
EU, while biovar 1 is very rare, it has been reported once in horses in Croatia (Fretin et al., 2008) and
a clinical case has been reported in cattle in the USA (Ewalt et al., 1997).
AHL assessment on the infection with Brucella abortus, B. melitensis and B. suis
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Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Experimental infections have succeeded in several wild species, and probably both B. abortus and
B. melitensis can be transmitted experimentally to most if not all wild mammals.
The experimental susceptibility of wild species to B. suis biovars remain to be established.
Parameter 4 – Experimentally susceptible domestic species (or family orders)
B. abortus and B. melitensis naturally induced infections have been reported in practically all
domestic mammal species. Thus, both infections can be probably transmitted experimentally to most if
not all domestic mammals.
Apart from pigs, cattle and horses, the domestic species experimentally susceptible to B. suis
biovars remain to be properly established (with the exception of infection by biovar 4 in moose
(Dieterich et al., 1991)).
However, infections in cattle by B. suis biovar 2 seem to be extremely rare, and in this case, at
least considering the reported information, it seems that the infection is not followed by clinical (i.e.
pathological) events (Fretin et al., 2013).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
B. abortus
No wild species have been proven as a natural reservoir. However, when human activity has
impacted wildlife population dynamics, and where the infection is widespread in wildlife (i.e. the case
of the bison and elk in the Yellowstone Park in the US – see comments in Section 3.1.2.4), some wild
species could behave as a reservoir for both domestic cattle and wildlife (Cross et al., 2013).
B. melitensis
No wild species have been proven as a natural reservoir. In general, and particularly in Europe, wild
ruminants are not regarded as reservoirs (maintenance hosts) for Brucella (Mu~noz et al., 2010).
However, exceptions may be found when human actions alter wildlife dynamics, such as in the Bargy
Ibex case (Mick et al., 2014).
B. suis
This complex species is composed by ﬁve biovars, which reﬂects the different types of
epidemiological occurrence in wild species. Wild boar is the natural reservoir of B. suis biovar 2. The
infection is also frequent in European hares, although non-existent in other native hare species at least
in the Iberian Peninsula (Mu~noz et al., 2010), but the epidemiological role of hares remains unclear
(Mu~noz et al., 2010). The epidemiological relevance of the rare cases of B. suis biovar 2 in cattle and
horses is unknown.
Feral pigs (Sus scrofa) and peccaries (Tayassuidae) are considered the natural reservoirs of B. suis
biovars 1 and 3. These two last biovars are not present in the EU, with a rare exception for biovar 1
reported in horses (Fretin et al., 2008), and whose epidemiological signiﬁcance is unknown.
Arctic foxes (Vulpes lagopus) and wolves (Canis lupus) may be infected by B. suis biovar 4 after
eating infected reindeer (considered the reservoir of this biovar), but it is unknown if these carnivores
are a reservoir or mere dead-end hosts. In the former Soviet Union and the Baltic countries, small
rodents have been considered the natural reservoir of B. suis biovar 5, an infection of little
epidemiological signiﬁcance (EFSA, 2009; OIE, 2016). However, no recent reports are available.
Parameter 6 – Domestic reservoir species (or family/orders)
B. abortus: cattle (Bos taurus)
B. melitensis: sheep (Ovis aries) and goats (Capra hircus)
B. suis
• biovar 1, 2 and 3: pigs;
• biovar 4: domesticated reindeer/caribou;
• biovar 5: small rodents.
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3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
B. abortus/B. melitensis
B. abortus is found worldwide in cattle-raising regions except Japan, Canada, most European
countries, most USA states, Australia and New Zealand, where it has been eradicated. B. melitensis is
found in the Mediterranean countries, the Middle East, the Arabian Gulf, Latin America, Africa and Asia.
Data on the prevalence and incidence of B. abortus or B. melitensis infections in domestic animals not
submitted to ofﬁcial control are very difﬁcult to get. The prevalence and incidence in domestic na€ıve
populations which are neither vaccinated nor participating in any ofﬁcial sanitary intervention are
usually very high, and depend largely on the time that has elapsed after the onset of disease in a
given herd or ﬂock. As example, in the early phases (before 1990) of ofﬁcial eradication programmes
in Spain, herd prevalence ranged between 20% and 62% depending on the animal species and the
regions considered. The individual prevalence (0.3–18.5%) depended on the region, animal species
involved, and the technical characteristics of the programme (Blasco, 1986, 1990).
In contrast, when ofﬁcial interventions are applied, the prevalence/incidence ﬁgures are much lower
but highly variable depending on the countries, the species, and the characteristics and degree of
application of the programmes implemented. Suitable information on these parameters is available in
EU Member States (MS) in which control and eradication campaigns are performed.
The last data available for 2016 (https://ec.europa.eu/food/funding/animal-health/national-veterina
ry-programmes_en) on the expected collective prevalence/incidence in these affected countries are
summarised in Table 1.
Individual prevalence/incidence is zero in the brucellosis ofﬁcially free countries. The last data
available (2016) on the expected individual prevalence are summarised in Table 2.
Table 1: Herd prevalence and incidence in cattle, sheep and goat herds/ﬂocks infected with
Brucella in the EU Member State areas in which eradication programmes are coﬁnanced by
the EU, hence do not include all herds and ﬂocks in the country (in particular those of OBF
areas) (year 2016)
Country
Bovine Small ruminants
Herds
tested
% Prevalence % Incidence
Flocks
tested
% Prevalence % Incidence
Portugal 33,560 0.18 0.12 60,452 0.62 0.38
Spain 110,564 0.03 0.02 65,719 0.09 0.06
Italy 33,822(1) 0.48 0.48 38,158 0.78 0.61
Greece Nd Nd Nd 22,950 0.02 0.01
Croatia Nd Nd Nd 20,176 0.1 0.1
(1): Including buffaloes (1,282 herds; prevalence 1.01%; incidence 0.62%). Nd: not indicated.
Source: https://ec.europa.eu/food/funding/animal-health/national-veterinary-programmes_en
Table 2: Expected animal prevalence of Brucella infection in cattle, sheep and goat in the EU
Member State areas in which eradication programmes are co-ﬁnanced by the EU (year
2016)
Country
Bovine Small ruminants
No. animals
to be tested
individually
% Prevalence
No. animals
to be tested
individually
% Prevalence
Portugal 899,600 0.02 1,558,000 0.1
Spain 3,874,200 0.002 8,490,600 0.01
Italy 1,004,279(1) 0.37 2,302,009 0.69
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In the absence of anthropogenic interventions in wildlife management that can modify the wildlife
population dynamics (e.g. artiﬁcial winter feeding that can lead to increase of wildlife density and
facilitates the animal contacts and the ensuing transmission), the prevalence of B. abortus/
B. melitensis infections in wildlife species in the EU is considered very low or null (Mu~noz et al., 2010;
Garin-Bastuji et al., 2014; Mick et al., 2014).
B. suis
Infections caused by B. suis biovars 1 and 3 have been eradicated from domestic swine in several
countries, including Canada, Australia and the USA. However, these infections still occur in wild and
feral pigs, and can spread to domestic herds. In some studies, the individual prevalence in wild and
feral swine ranged from 14% to 44%, and varied over time (CDC, 2005).
As the EU is considered as ofﬁcially free from porcine brucellosis, data on the natural prevalence
and incidence of B. suis biovar 2 infection in pigs are also scanty. The prevalence/incidence in intensive
herds is considered insigniﬁcant (EFSA, 2009). However, outbreaks can be important in outdoor
breeding herds due to spillover from infected wild boar. The percentage of infected pigs in na€ıve herds
affected by a new outbreak is usually very high (15% to over 50%). The apparent prevalence of
B. suis biovar 2 infection in wild boar is extremely high (25–45%) in the several EU Member States
(Garin-Bastuji and Hars, 1999, 2001; EFSA, 2009; Mu~noz et al., 2010).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
B. abortus/B. melitensis
As indicated above, suitable data on the natural case morbidity rate of brucellosis in na€ıve domestic
animal populations are not available. Accordingly, only data obtained from artiﬁcially exposed animals
are available. The most frequent clinical manifestation of B. abortus/B. melitensis infections is abortion.
When brucellosis-free and unvaccinated cows are artiﬁcially exposed at the critical period of pregnancy
(usually mid pregnancy) to B. abortus virulent challenge doses (5 9 107 – 5 9 108 CFU), 80–100% of
the animals develop severe infections resulting in abortions in 75–100% of cows exposed (Moriyon
et al., 2004). When challenge exposure is performed with similar B. melitensis doses in pregnant
sheep and goats, the clinical consequences are very similar, with infection/abortion rates close to
100% (Verger et al., 1995; Barrio et al., 2009).
B. suis
In B. suis, biovar 2 naturally infected swine na€ıve herds, intraherd prevalence can be as high as
75–80%, with a very high proportion of abortions (25–60%) and infertility (30–80%) (Garin-Bastuji
and Hars, 1999, 2001; EFSA, 2009; Dieste et al., 2011).
Mortality
Parameter 3 – Case-fatality rate
The case-fatality rate in naturally induced infections in domestic or wild animals is very low. Deaths
are very rare in adult animals of most species; however, high B. abortus doses can be lethal in
experimentally infected moose, and possibly also in bighorn sheep (Forbes et al., 1996). Fatality rate in
humans is also very low (Pappas et al., 2006).
Country
Bovine Small ruminants
No. animals
to be tested
individually
% Prevalence
No. animals
to be tested
individually
% Prevalence
Greece Nd Nd 4,279,000 0.02
Croatia Nd Nd 450,000 0.01
(1): Including buffaloes (260,375 animals; expected prevalence: 0.81%). Nd: not indicated.
Source: http://ec.europa.eu/dgs/health_foodsafety/funding/cff/animal_health/vet_progs_en.htm
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3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
Situation worldwide
Brucellosis is probably the commonest zoonotic infection worldwide, and whose global incidence
has changed over the past decade because of various sanitary, socioeconomic, and political reasons,
together with the evolution of international immigration and travel. Areas traditionally considered to be
endemic (EU Mediterranean countries for example) have signiﬁcantly improved the control of the
disease, but the disease is still present. However, brucellosis is emerging strongly in the Near East and
Asia (Pappas et al., 2006), and probably also in Africa (Ducrotoy et al., 2015). The incidence of human
brucellosis worldwide was summarised in Dean et al. (2012a), with European estimates of 4-32 per
100,000 per year in Greece, 0.03 in Germany, 1.40 in Italy, and global reported maximum of 52-269 in
Iraq.
Situation in the EU (see also Section 3.1.1.7 below)
A total of 437 conﬁrmed human cases were reported in 2015 (EFSA, 2016) with a notiﬁcation rate
of 0.08 cases per 100,000 inhabitants. These primarily occurred in Greece (110 cases), Italy (106),
Portugal (47), Spain (n = 39), Germany (n = 44), Bulgaria (37), France (n = 19), Sweden (n = 13) and
the United Kingdom (n = 12) while other MS had less than 10 cases.
Brucella species information was missing for 71.5% of the 347 conﬁrmed cases reported. Of cases
in which bacterial isolation was conducted, 85.6% were due to B. melitensis, 2.1% to B. abortus and
12.4% to other Brucella species. In contrast to B. suis biovars 1, 3 and 4, B. suis biovar 2 has rarely
been isolated from humans and non-porcine animal species. It can be considered less pathogenic to
humans than other biovars and its zoonotic role is questioned in non-immunocompromised hosts
(Godfroid et al., 2013; Mailles et al., 2016). Similarly, in cattle as well as in small ruminants, this biovar
has been only isolated in singleton serological reactors in brucellosis ofﬁcially free EU member states
(Belgium (Fretin et al., 2013), France, Poland (Szulowski et al., 2013)), in the absence of any clinical
sign or spread to other ruminants. However, precise information on the Brucella in cause is available
only after its typing at biovar level; therefore at the initial conﬁrmation of human or animal brucellosis,
this will be difﬁcult to assess and the control measures should be taken as it would be dealt with other
more pathogenic species/biovars.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
In contrast to other bacterial pathogens, selection for antibiotic resistance seems unimportant in
brucellosis. This may relate to the absence of plasmids and lysogenic phages in the genus Brucella
(Moreno, 1998). Moreover, due to economical, epidemiological and public health reasons, antibiotic
treatment of brucellosis has been precluded in domestic animals, thus limiting the development of
antibiotic resistance. Accordingly, resistance is not considered a signiﬁcant issue in treating human
brucellosis (Maves et al., 2011).
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
Brucellae remain conﬁned to the lymph nodes close to entry sites for 2–3 weeks, and then reach
the blood via the efferent lymphatics; bacteraemia then leads to a generalised infection in
reticuloendothelial organs, lymph nodes distant from entry sites, genital and extragenital organs and
accessory sexual glands.
The precise duration of B. abortus, B. melitensis and B. suis infections has not been properly
established in the different domestic species, but it is widely accepted that only a low proportion
(10–15%) of infected animals develop a self-cure mechanism, while most remain infected for life,
excreting the bacteria intermittently to the environment (Nicoletti, 1980; EFSA, 2009).
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Parameter 2 – Presence and duration of latent infection period
The duration of the latent status until the animals develop the disease is highly variable, usually
showing an abortion during their ﬁrst or second pregnancy (Plommet et al., 1973; Lapraik and Moffat,
1982).
Brucella-induced latent infections are transmitted from infected dams to offspring either during
pregnancy or perinatally (usually through milk). Latently infected animals are apparently healthy and
show negative responses in the indirect immunological diagnostic tests, being thus very dangerous
epidemiologically. Latent infections have been reported in up to up to 10% of the offspring born to
B. abortus infected cattle (Plommet et al., 1973; Lapraik and Moffat, 1982), and also in B. melitensis
infected goats (Renoux, 1962) and sheep (Grillo et al., 1997). Latent infections have not been reported
in B. suis infected pigs, but they are believed to also occur these with variable frequency (EFSA,
2009).
Despite its low frequency, latent infection is one of the most frequent and dangerous causes of
brucellosis transmission. If the objective is eradicating the infection, keeping replacements from
Brucella positive animals should be avoided.
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
Some Brucella species can survive for long periods outside the host. Dryness, high temperatures
and direct sunlight exposure are very unfavourable for Brucella survival. Under favourable conditions,
such as pH > 4, low temperatures, high humidity and the absence of direct sunlight, Brucella spp. may
survive for relatively long periods in aborted fetuses and fetal membranes, faeces and liquid manure,
water, wool and hay, as well as on equipment and clothes. Brucella spp. are able to withstand drying
particularly in the presence of organic material and can then remain viable in dust and soil for
relatively long periods. Survival is prolonged at low temperatures, especially in snow and ice. Since the
presence of DNA in selected matrixes or the environment is not representative of the true survival
ability of Brucella, no comments will be made on this topic. As an example, the persistence of B. suis
on fomites varies from 4 h to 56 days (Ryan, 2010; US-EPA, 2010a,b; Calfee and Wendling, 2012).
Brucella species can persist for several weeks in soil (Franz et al., 1997; Charters, 1980) and in dust
(Franz et al., 1997). B. abortus was reported to persist 66 days in wet soil, 48–73 days in soil at 90%
humidity and < 4 days in dried soil (Nicoletti, 1980). B. abortus can persist in fetal tissues, soil or
vegetation for several weeks or even months depending upon the season, temperature and sunlight
(Aune et al., 2012). In bovine and bison fetuses deployed in February, March, April and May,
B. abortus persistence was 81, 77, 69 and 25 days, respectively (Aune et al., 2012). B. abortus
persisted 10–43 days at B. abortus contaminated sites associated with bison births or abortions for
7–26 days (Aune et al., 2012).
B. suis can persist at least 28 days in soil held at 5°C or 22°C (US-EPA, 2010a,b). However, in some
study, this pathogen has been reported, surprisingly, to survive for 4 years in soil (Mollaret and
Bourdin, 1973).
Depending on temperature and pH, B. abortus can persist in water from less than 1 to 77 days in
water (Nicoletti, 1980; Falenski et al., 2011). B. melitensis and B. suis can persist for 1–7 days in
dechlorinated water (Gilbert and Rose, 2012).
The survival of Brucella in milk and dairy products is highly variable from only few seconds to more
than 4 months, depending on the Brucella species, the pH and temperature of preservation (for a
review, see Garin-Bastuji and Blasco, 2016). Disinfectants reported to kill Brucella on contaminated
surfaces include 2.5% sodium hypochlorite, quaternary ammonium compounds, 2–3% caustic soda,
20% freshly slaked lime suspension or 2% formaldehyde solution (all tested for 1 h). Ethanol,
isopropanol, iodophores, substituted phenols or diluted hypochlorite solutions can be used on
contaminated skin; alkyl quaternary ammonium compounds are not recommended for this purpose.
Autoclaving (moist heat of 121°C for at least 15 min) can be used to kill Brucella species on
contaminated equipment. These organisms can also be inactivated by dry heat (160–170°C) for at
least 1 h. Boiling for 10 min is usually effective for liquids. Xylene (1 mL/L) and calcium cyanamide
(20 kg/m3) are reported to decontaminate liquid manure after 2–4 weeks. Brucella species can also be
inactivated by gamma irradiation and pasteurisation (Ryan, 2010; Garin-Bastuji and Blasco, 2016).
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3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
The main routes of transmission between animals and between animals and humans are
summarised in Figure 1.
Fetuses can be infected vertically, allowing the development of latent carriers. The heavily
contaminated placenta and aborted fetuses become the main source of infection for humans (direct
contact) and other animal hosts. Humans may also acquire infection eating unpasteurised dairy
products, primarily or, exceptionally, raw or undercooked contaminated animal organs (like liver, blood
and spleen) and meat.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
See Figure 1 above.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
Data on the incidence of animal brucellosis have been commented above (see Section 3.1.1.2). In
the absence of vaccination, the risk of transmission of brucellosis between animals in infected
environments is very high. The incidence in humans has been reported to be highly correlated
(r = 0.82) to the incidence of brucellosis in animals (Lee et al., 2013). Accordingly, when the disease is
controlled in the animal hosts, a signiﬁcant decrease is seen in human brucellosis incidence achieved.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
Several statistical methods have been applied to the quantitative study of brucellosis transmission in
animals and humans. These methods have provided the basis for identifying key epidemiological
parameters as the basic reproductive ratio (R0) or the effective reproductive ratio (Re), that indicates
Figure 1: Brucella life host cycle (adapted from Moreno (2014))
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the number of secondary infections for each infectious individual during ongoing transmission (for a
review see Heffernan et al. (2005)). Several R0 values have been reported or hypothesised for
brucellosis (Table 3) but these ﬁgures are not straightforward because transmission dynamics is
complicated by multiple interactions (Beauvais et al., 2016; Hou and Sun, 2016).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
Presence in animals
Bovine brucellosis
The list of countries and regions Ofﬁcially Brucellosis-Free (OBF) is laid down in Annex II of the
current version of Commission Implementing Decision (EU) 2016/1681.
‘not OBF yet’
For 2015, 938 positive or infected cattle herds were reported in total in the non-OBF regions of the
non-OBF MS (967 in 2014), i.e. a herd prevalence of 0.28%.
Sheep and goat brucellosis
The list of countries and regions Ofﬁcially Brucella melitensis-free (ObmF) is laid down in Annexes I
and II to Commission Decision 2010/695/EU.2
Maps are provided in the European Union summary report on zoonoses (EFSA, 2016).
During the period 2005–2013, the overall proportion of sheep and goat ﬂocks positive to
B. melitensis in the EU showed a decreasing trend. In 2014, the decline continued from 0.11% in 2013
to 0.09% in 2014, the lowest prevalence ever reported. In the non-ObmF regions of the non-OBmF
MSs, the overall prevalence of B. melitensis-positive sheep and goat ﬂocks decreased from 0.45% in
2012 to 0.29% in 2015.
Porcine brucellosis
The EU is considered as ofﬁcially free from this infection in domestic swine, although B. suis biovar
2 cases have been reported sporadically in several MSs in outdoor pig farms, in particular: Belgium,
Croatia, Finland, France, Germany, Italy and Poland. Moreover, a relevant number of samples from wild
boar (1,393 in Germany, 252 in Italy and 156 in Spain in 2014) and hares (16 in Germany in 2014)
were reported to be infected by B. suis biovar 2. Maps are provided in the European Union summary
report on zoonoses (EFSA, 2016).
Table 3: Examples of reproductive ratio (R0) ﬁgures calculated or hypothesised for animal
brucellosis in different scenarios
R0 values Species Country Reference
1.75 Bison USA Hobbs et al. (2015)
1.2 Sheep Mongolia Zinsstag et al. (2005)
1.7 Cattle Mongolia Zinsstag et al. (2005)
2 Sheep Hypothesised Moreno (2014)
< 1 – > 3 Sheep/cattle Mongolia Racloz et al. (2013)
1 Commission Implementing Decision (EU) 2016/168 of 5 February 2016 amending the Annexes to Decision 2003/467/EC
establishing the ofﬁcial tuberculosis, brucellosis and enzootic-bovine-leukosis-free status of certain Member States and regions
of Member States as regards bovine herds. OJ L 32, 9.2.2016, p. 153–157.
2 Commission Decision of 17 November 2010 amending the Annexes to Decision 93/52/EEC as regards the recognition of
Estonia, Latvia and the Autonomous Community of the Balearic Islands in Spain as ofﬁcially free of brucellosis (B. melitensis)
and amending Annexes I and II to Decision 2003/467/EC as regards the declaration of Estonia as ofﬁcially tuberculosis-free
and ofﬁcially brucellosis-free as regards bovine herds. OJ L 303, 19.11.2010, p. 14–17.
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Presence in humans
A total of 449 human brucellosis cases (of which 437 were conﬁrmed, and most due to
B. melitensis and B. abortus), were reported in the EU in 2015 (EFSA, 2016).
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
See above in Sections 3.1.1.1 and 3.1.1.7 Parameter 1.
Risk of introduction
Not applicable. The animal disease is already present in several European countries. Control
measures keep other countries Member States ofﬁcially free.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Brucellosis caused by B. abortus (cattle and buffaloes), B. melitensis (small ruminants) and B. suis
(swine) lacks pathognomonic symptoms and its diagnosis is based on the existing direct and indirect
tests (OIE, 2016) (see Sections 3.1.4.1 and Tables A.1, A.2 and A.3 in Appendix A), the latter being
those applied routinely in surveillance and control and eradication programmes. Detailed information of
the availability, feasibility and effectiveness of the diagnostic tests is given below in Section 3.1.4.1.
Control tools
Parameter 2 – Existence of control tools
There are two possible strategies which exist to ﬁght against brucellosis in ruminants: (1) a control
programme based on mass (whole-ﬂock/herd) vaccination or (2) an eradication programme based on
test and cull, combined with vaccination. In both cases, the use of adequate vaccination procedures
and diagnostic tests is of paramount importance. A detailed description is made in Section 3.1.4.2.
Blasco and Molina-Flores (2011) provide considerable detail on control and eradication of Brucellosis
stating that Brucellosis can be ﬁrst controlled (essentially by vaccination), and once the prevalence has
decreased to reasonable levels the disease can be eradicated from a herd/ﬂock by test and culling
procedures (combined or not with vaccination), or by full depopulation. The authors provide a simple
decision tree which should be taken into consideration by decision makers to select the most
appropriate strategy according the different epidemiological situations. Independent of the prevalence
of infection, the quality and degree of organisation of the national veterinary services is the limiting
factor.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is presence
See above in Section 3.1.1.7.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation (milk, growth,
semen, meat, etc.)
There are very few well-documented studies on the production losses and the economic impact of
brucellosis that take into account all aspects of the disease impacting the animal industry. Production
losses can be divided broadly in direct (due to the pathological condition itself) and indirect (due to
associated causes).
A summarised description of brucellosis losses is made in Figure 2.
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Little is known about how brucellosis affects animal production quantitatively. A standardised
methodology has been applied to the estimation of the direct disease costs and the human health and
animal welfare impacts associated with 34 endemic diseases of livestock in Great Britain, but
unfortunately, this study did not include brucellosis (Bennett and Ijpelaar, 2005).
The main clinical feature of brucellosis is late abortion in cattle, pigs, sheep and goats. Among the
seropositive cattle, it has been estimated empirically that 10–50% abort and 20% of these remain
infertile (Bernues et al., 1997). Having aborted, animals are often not milked and the entire lactation is
lost. Besides abortions, perinatal mortality was also estimated empirically between 5% and 20%, and
moreover, it was hypothesised that 1% of cows with abortions may die (Bernues et al., 1997). These
authors estimated also theoretically a loss of 10–25% of total milk yield among the seropositive cows.
These theoretical values were established many years ago in cattle in a particular epidemiological
situation in the north of Spain. Despite this, these ﬁgures have been classically considered as the
reference standard for losses caused for brucellosis no matter the animal species and the
epidemiological conditions considered. In a study on bovine brucellosis (Santos et al., 2013), and
based in part on these theoretical considerations, the following losses were estimated:
• 15% incidence of abortions in infected heifers and cows;
• an average of 2 months of temporary infertility for each infected cow and heifer, considering
that 20% of cows that abort become sterile;
• an incidence rate of perinatal mortality of 10% for calves born from infected cows or heifers;
• 15% loss of the total milk yield of infected cows;
• 5% loss in meat production by infected cows;
• 1% mortality risk for infected cows that aborted (i.e. 0.15% of infected cows and heifers);
• an increase in the rate of replacement corresponding to 15% of the infected cows and heifers;
• replacement costs of infected bulls, considering roughly half of the seroprevalence of heifers,
an average bull/cow ratio of 1/25, and same approach for calculating replacement as for
females.
Figure 2: Direct and indirect costs of brucellosis (Bruce and Rushton, 2014)
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In summary, the direct production losses due to brucellosis have been estimated empirically, and
only in cattle. Accordingly, the available losses reported are probably inaccurate, and precise
information is lacking in the case of small ruminants and pigs.
Regarding porcine brucellosis, although it has been eradicated from the domestic pig population in
Europe for decades, B. suis biovar 2 infection in wild boar (which is a sustainable infection in almost all
European wild boar populations) is of major concern for pigs reared outdoors, should brucellosis
control programmes in domestic pigs be implemented in the EU Member States (Godfroid et al., 2013).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Transmissibility between animals and humans
Parameter 1 – Types of routes of transmission between animals and humans
Brucella is easily transmitted from animals to humans. Humans become infected either through
direct contact with infected animals or consumption of unpasteurised contaminated dairy products and
selected raw or undercooked contaminated animal organs (like liver, blood and spleen). As the
infectious dose is very low for humans, infection is usually an occupational risk for farmers,
veterinarians, abattoir workers, laboratory personnel and others who work with animals and a risk for
those who consume unpasteurised products. The increase in business and leisure travel to brucellosis-
endemic countries has led to the importation of the human disease into non-endemic areas.
Parameter 2 – Incidence of zoonotic cases
The prevalence of brucellosis in humans depends upon several factors such as dietary habits,
methods of processing milk and milk products, husbandry practices and environmental hygiene.
Brucellosis causes more than 500,000 human infections per year worldwide. The disease has a limited
geographic distribution, but it remains a major public health problem in the Mediterranean region,
Western Asia, parts of Africa and Latin America (Pappas et al., 2006). The situation in the EU has been
described in detail in Section 3.1.1.3.
Transmissibility between humans
Parameter 3 – Human to human transmission is sufﬁcient to sustain sporadic cases or community-level
outbreak
See comments in the next Parameter.
Parameter 4 – Sporadic, endemic, epidemic or pandemic potential
Human to human transmission of brucellosis is exceptional, and these exceptional cases have been
reported. As an example, two physicians who assisted the surgical delivery of a placenta in an infected
woman developed Brucella melitensis infection (Mesner et al., 2007). Sexually transmitted cases have
been suspected but never really proven (Meltzer et al., 2010). Humans are considered thus a dead-end
host of the disease.
The severity of human forms of the disease
A speciﬁc meta-analysis has been conducted on this topic (Dean et al., 2012a). Brucellosis is a
multisystemic disease with a broad spectrum of symptoms. Asymptomatic infections are common. In
symptomatic cases, the disease is extremely variable and the clinical signs may appear insidiously or
abruptly. Typically, brucellosis begins as an acute febrile illness with nonspeciﬁc ﬂu-like signs.
Splenomegaly, hepatomegaly, coughing and pleuritic chest pain are sometimes seen. Gastrointestinal
signs including anorexia, nausea, vomiting, diarrhoea and constipation occur frequently in adults but
less often in children.
The disease is considered non-fatal (mortality rate of around 1% or less). However, when the
diagnosis or treatments are not made properly, severe complications are common. Brucellosis causes
one case of endocarditis and four neurological cases per 100 patients. One in 10 infected males suffers
from epididymo-orchitis. Arthralgia, myalgia and back pain affect around half of the patients (65%,
47% and 45%, respectively).
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Parameter 5 – Disability-adjusted life year (DALY)
DALY for a given disease are calculated by summing the years of life lost due to premature
mortality (YLL) in the population and the equivalent healthy years lost due to disability for incident
cases of the health condition (YLD). DALY estimates for brucellosis are based on the fact that is a non-
fatal disease. So, the YLL part of calculations goes to zero. A brucellosis disability weighting of 0.2 has
been proposed for DALY calculation, based on the pain and impaired productivity known to result from
infection, and a median duration of untreated brucellosis of 3.1 years (Roth et al., 2003). Under this
assumption, the cost-effectiveness and economic beneﬁt for human society and the agricultural sector
of a mass vaccination programme against ruminant brucellosis was modelled (Roth et al., 2003). The
intervention consisted of a 10-year mass vaccination of Mongolian livestock using Rev.1 vaccine in
small ruminants and S19 vaccine in cattle. Cost-effectiveness, expressed as cost per DALY averted, was
the primary outcome. In a scenario of 52% reduction of brucellosis transmission between animals
achieved by mass vaccination, it was estimated that a total of 49,027 DALY could be averted.
A DALY estimation was made in Kenya (http://es.slideshare.net/ILRI/brucellosis-inkenya) based on
a reported number of 77,937 brucellosis cases in year 2012, and assuming average disease duration of
six months, a disability weight of 0.19, and no mortality. The total DALY lost was 7,352 (i.e. 0.190
DALY per 1,000 people). DALY lost were 4,862 in males (i.e. 0.253 DALY per 1,000 people) and 2,490
in females (0.128 per 1,000 people). Extrapolating these Kenyan incidence data, the DALY for human
brucellosis in Sub-Saharan countries ranged from 140,220 (considering only the reported cases) to
632,400 (considering 50% underreporting).
Another DALY estimate in Sudan using a 0.2 disability weight, concluded that the healthy years lost
by an infected person accounted 7.5 DALY (Elkhansaa and Angara, 2014).
The availability of effective prevention or medical treatment in humans
Parameter 6 – Availability of medical treatment and their effectiveness (therapeutic effect and any
resistance)
There are suitable treatments for human brucellosis. The prophylaxis of human brucellosis has to
be based on three essential measures:
• awareness campaigns to educate the population on the major transmission risks (essentially,
direct contact with animals and eating raw milk products);
• suitable food safety legislation and implementing measures avoiding the arrival to the markets
of contaminated dairy products;
• the reduction/elimination of the infection in the animal hosts through suitable control and
eradication campaigns. This last measure is, without any doubt, the most relevant for the
deﬁnitive eradication of human brucellosis.
In addition, the antibiotic treatment is prolonged. A review of the efﬁcacy of the FAO/WHO
recommendations is reported by Ariza et al. (2007).
Parameter 7 – Availability of vaccines and their effectiveness (reduced morbidity)
No vaccines are available for human brucellosis.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Brucellosis is considered as a major contributor to animal suffering, causing fever, abortions,
stillbirths and the birth of weak offspring, with the ensuing increase of perinatal mortality. Animals that
abort may retain the placenta and develop endometritis and infertility. Animals usually abort only once,
but subsequent chronic infertility is quite frequent. Milk yield is signiﬁcantly reduced in infected animals
but clinical signs of mastitis are uncommon. Acute orchitis and epididymitis can occur in males, and
may result also in infertility. Arthritis and hygromas are seen occasionally. Deaths are very rare except
in the fetus or new-born.
Studies on the impact of brucellosis on animal welfare beyond the clinical symptoms described
above are lacking.
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3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
In the EU, brucellosis due to B. abortus or B. melitensis have been reported only sporadically in
wild ungulates such as ibex (Capra ibex), chamois (Rupicapra sp.) and red deer (Cervus elaphus)
(Gortazar et al., 2007; Mick et al., 2014). However, these wild animals are considered occasional end
hosts of brucellosis transmitted from infected livestock, rather than a true reservoir of the disease
(Gortazar et al., 2007). Moreover, both infections are usually non-lethal in these wild species, which
appear as of ‘Least concern’ in the IUCN list.
Brucellosis due to B. suis biovar 2 is reported frequently in the EU affecting the Eurasian wild boar
(Sus scrofa) and the European brown hare (Lepus europaeus), which are considered the natural
reservoirs of porcine brucellosis in Continental Europe. This infection is non-lethal in these wild species.
Moreover, none of these two wild species appear as endangered or vulnerable in the IUCN list.
Parameter 2 – Mortality in wild species
Brucellosis is a non-fatal disease, being this issue of minor concern.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
B. suis biovar 2 infection is well established and persists naturally in the Eurasian wild boar
(Sus scrofa) and the European brown hare (Lepus europaeus), these wild species being the natural
reservoir of this infection in Continental Europe, and the main reservoir for domestic pigs. This
infection is non-lethal in any of these wild species.
It has been questioned if B. abortus and B. melitensis can persist naturally in wildlife, being thus a
reservoir for both human and domestic animals (Rhyan et al., 2013).
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Brucella species can be easily cultured from infected animals. Also, these bacteria can be
transferred, multiplied and stored easily. An intentional contamination of food or water with pathogenic
Brucella species could pose a threat with a low mortality rate but with a very high attack rate. Some
Brucella (particularly B. melitensis and B. suis biovars 1 and 3) are highly infectious through oral/
aerosol routes and, moreover, low doses are infective for humans and also for animals. Altogether,
these characteristics make of this pathogen an attractive candidate to be used as a potential agent for
biological warfare purposes (Doganay and Doganay, 2013).
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
The Brucella genus is listed in the OIE list of notiﬁable terrestrial and aquatic animal diseases and in
the CFSPH bioterrorism pathogens. See http://www.cfsph.iastate.edu/Products/resources/WallChart.pdf
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
Pathogenic Brucellae are listed in the Encyclopaedia of Bioterrorism Defence of Australia Group.
See: http://www.defence.gov.au/health/infocentre/journals/ADFHJ_sep00/ADFHealthSep00_1_3_099_
106.pdf
Parameter 3 – Included in any other list of potential bioagroterrorism agents
Pathogenic Brucella are speciﬁed in the select agent rules implemented by USDA APHIS and the
Centers for Disease Control and Prevention (CDC) of the Department of Health and Human Services
(HHS) of the US and overlap with diseases and agents/toxins listed by APHIS, CDC and Code of
Federal Regulations of the US (CFR) 121.4. See: https://www.fas.org/sgp/crs/terror/RL32521.pdf
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3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
As indicated above (see Section 3.1.1.8), several diagnostic tests are available, recognised by the
OIE, and used for surveillance/eradication in most countries worldwide (EFSA, 2009). These OIE tests
and their main applications are summarised in Tables A.1, A.2 and A.3 (Appendix A).
Direct bacteriological isolation is the most speciﬁc test for the conﬁrmation of Brucella. Both
molecular and microbiological tests can be used for identiﬁcation and typing. The vaccine strains
(B. abortus strains S19 and RB51 and B. melitensis Rev.1) can be distinguished from their
corresponding virulent ﬁeld counterparts by both molecular (polymerase chain reaction (PCR) and
related molecular tests) and classic microbiological criteria. Despite their usefulness for identiﬁcation
and typing, molecular tests are not fully suitable for the direct diagnosis from ﬁeld samples. Serology is
the most adequate for diagnosis at population level and is used for a presumptive diagnosis or for
surveillance to screen herds/ﬂocks. Serological tests used in sheep, goats, cattle and pigs include the
buffered Brucella antigen tests (Rose Bengal and buffered plate agglutination tests), complement
ﬁxation, indirect or competitive enzyme-linked immunosorbent assays (ELISAs) and the ﬂuorescence
polarisation assay (FPA) (EFSA, 2006; EFSA, 2009; OIE, 2016). Other serological tests include gel
precipitation tests with Native Hapten (NH) or cytosolic proteins (suitable for ruminants), the serum
agglutination test (a test used in all animal species with controversial results), and the brucellin skin
test (for use in all animal species). ELISAs or the Brucella milk ring test (MRT – this only for use in
cattle) can be used also to screen dairy herds/ﬂocks by detecting antibodies in milk (OIE, 2016).
In vaccinated cattle, the NH-based gel precipitation tests are sometimes used to diagnose infected
animals in vaccination contexts (OIE, 2016).
The brucellin allergic skin test can be used to test unvaccinated animals for discriminating the true
brucellosis infected animals from those giving false positive serological reactions (FPSR) in serological
tests (generally due to cross-reactions with other gram-negative bacteria) (OIE, 2016).
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
Direct tests (see Table 4) are very speciﬁc (particularly the classical bacteriology) for the diagnosis
of brucellosis. However, since only the indirect tests are used for surveillance/eradication programmes,
comments on diagnostic accuracy (diagnostic sensitivity (DSe) and diagnostic speciﬁcity (DSp)) will be
focused exclusively in the immunological tests.
Because of different background ﬂora, sera from Brucella-free animals can produce signiﬁcantly
different background reactivity depending upon their origin. Therefore, cut-offs obtained with animals
from Brucella-free countries and infected animals from endemic areas as negative and positive
controls, respectively (Nielsen et al., 1998, 2007), must be interpreted bearing in mind this problem.
Tests for diagnosing brucellosis in small ruminants and cattle (B. melitensis and
B. abortus infections)
The EFSA meta-analytic report (EFSA, 2006) as well as literature data (using essentially the same
inclusion/exclusion criteria that those used in EFSA (2006)) were used to produce the diagnostic
accuracies summarised in Tables A.1 (Appendix A – sheep), A.2 (Appendix A – cattle) and A.3
(Appendix A – goats). Sensitive enough and reasonably speciﬁc tests are available, with the possibility
to combine more than one of these tests for a suitable diagnosis and culling policy (EFSA, 2006).
AHL assessment on the infection with Brucella abortus, B. melitensis and B. suis
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2017;15(7):4889
Table 4: OIE test methods available for the diagnosis of B. abortus, B. melitensis and B. suis
infections (Source: adapted from OIE (2016). Infection with Brucella abortus, B. melitensis
and B. suis)
Method
OIE test
prescription
Purpose
Population
freedom
from
infection
Individual
animal
freedom
from
infection(a)
Efﬁciency
of
eradication
policies(b)
Conﬁrmation
of clinical
cases(c)
Conﬁrmation
of suspect
cases(d)
Herd/ﬂock
prevalence
of infection –
surveillance
Direct Agent identiﬁcation
Staining
methods
– – – – + – –
Culture(k) – – – – +++ +++/++(d) –
PCR(e) – – – – + +/+(d) –
Indirect Detection of immune response(e),(f)
BBAT
(RBT,
BPAT,
Card
test)
Prescribed
for trade
+++ ++ +++ + + +++
FPA Prescribed
for trade
++ ++ + ++ + ++
CFT Prescribed
for trade
++ ++ +++/+(j) ++ + ++
I-ELISA Prescribed
for trade
+++ ++ +++ ++ + +++
C-ELISA Prescribed
for trade
+ – – + + +
BST Other tests +++ – + +++ +++ ++
SAT Other tests + + + – – +
NH and
cytosol
protein-
based
tests(g)
Other tests – – +/++(i) ++ ++ –
Bulk milk
tests(h)
Milk I-
ELISA or
Milk ring-
test
Other tests +++ – +++ – – +++
+++ = recommended method; ++ = suitable method; + = may be used in some situations, but cost, reliability, or other factors
severely limits its application; – = not appropriate for this purpose. CFT: complement ﬁxation test; I-/C-ELISA: indirect/
competitive enzyme-linked immunosorbent assay; FPA: ﬂuorescence polarisation assay; BST: Brucellin skin-test; SAT: standard
tube agglutination test; NH: native hapten.
(a): This applies only to herds/ﬂocks, countries or zones free from infection with Brucella.
(b): In order to improve the efﬁciency of eradication policies in infected herds/ﬂocks, it is recommended to associate tests in
parallel to increase the sensitivity of the diagnosis, i.e. two serological tests at least, e.g. BBAT or FPA and CFT or I-ELISA.
The sensitivity is further increased by a parallel testing in both serology and BST.
(c): In low-prevalence or almost-free zones, the predictive value of positive results to serological tests may be very low. In such
situation, the agent identiﬁcation is usually needed for conﬁrming clinical cases.
(d): In infected herds/ﬂocks, a positive result to any serological test may be considered as a conﬁrmation of a clinical case: (1)
In infected herds/ﬂocks, any reactor in any serological test should be considered as infected, (2) In low-prevalence or
almost-free zones, singleton serological reactors may be conﬁrmed by culture or BST (BST individual sensitivity is not 100%;
BST is, however, highly effective when interpreted at herd/ﬂock level), (3) In free countries or zones, suspect animals are
those positive to both a screening and a conﬁrmatory serological test (tests in series) and may be conﬁrmed by culture (and
or PCR) and/or BST.
(e): False-positive and false negative results may occur.
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Tests for brucellosis in pigs (B. suis infection)
Comments on diagnostic performance of the OIE tests in pigs are based on the meta-analytical
EFSA estimates (EFSA, 2009), as well as on more recent work (Mu~noz et al., 2012; Dieste-Perez et al.,
2015a). Highly sensitive and reasonably speciﬁc tests with the potential to combine more than one are
available (EFSA, 2009). However, serological testing in pigs is mainly useful to monitor herd status but
is not reliable enough for identifying individual animals infected. Evidence from the systematic review
suggests that indirect and competitive ELISAs could be suitable candidates because of their high DSe
and DSp (EFSA, 2009). However, these ELISA tests have not been fully evaluated and standardised in
pigs, and highly variable results are obtained when applied in the same population.
A major concern in porcine brucellosis ofﬁcially free countries is the presence of false positive
serological reactions (FPSR) in S-LPS-based tests. Little is known about the causes of FPSR in pigs,
but infections by Yersinia enterocolitica O:9 are considered the main responsible (EFSA, 2009). Neither
S-LPS- nor R-LPS-based tests are fully speciﬁc for differentiating porcine brucellosis from FPSR
(Appendix A). In addition to bacteriology and molecular tools, the brucellin skin test (BST) is
considered the only conﬁrmatory test discriminating between brucellosis and the infections caused by
Y. enterocolitica O:9 or other cross-reacting bacteria (EFSA, 2009; Dieste-Perez et al., 2014). However,
some serological tests based on cytosolic proteins can be a suitable and more practical alternative to
the BST (Dieste-Perez et al., 2015a).
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
A large variety of sample matrices can be cultured. Milk samples and vaginal swabs from aborted
animals are particularly useful for diagnosis in live animals. Brucella can also be cultured from aborted
fetuses (stomach contents, spleen and lung) or the placenta. The spleen, the whole lymph nodes,
udder and late pregnant or early post-parturient uterus, testis/epididymides, and accessory male sex
glands are the most reliable samples to collect at necropsy (De Miguel et al., 2011). These samples are
also suitable for direct PCR diagnostic procedures.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
Three live attenuated vaccines are currently available: B. abortus S19 and B. abortus RB51 (for
brucellosis cattle) and B. melitensis Rev.1 (for brucellosis in sheep and goats).
There are no vaccines against brucellosis induced by B. abortus/B. melitensis in camels, water
buffaloes and yaks, which are important domestic species cohabiting with small ruminants and cattle in
several breeding systems outside the EU.
The B. abortus S19 but not RB51 has been also proven effective against B. melitensis infection in
cattle (Jimenez de Bag€ues et al., 1991; Peniche Carde~na et al., 2009) and partially protective in red
deer (Arenas-Gamboa et al., 2009). B. abortus S19 vaccine is used empirically in water buffalo and yak
for the prophylaxis of brucellosis in some countries (e.g. Mongolia). However, no protection experiments
have been conducted in camel, water buffalo, yak, swine and other domestic livestock. Developments in
this area are required urgently. A major drawback of the S19 vaccine is that it is difﬁcult to distinguish
between cattle naturally infected from those vaccinated as adults, which is possible with the RB51
vaccine (Yang et al., 2013). Another disadvantage of the S19 and RB51 vaccines is that they can cause
abortion if given to pregnant cows (Smith and Ficht, 1990; Yang et al., 2013) and their virulence for
(f): The sensitivity and speciﬁcity of serological tests are far lower in pigs than in ruminants. Therefore, it is almost impossible to
implement a large-scale serosurveillance in a pig population (due to the lack of speciﬁcity). In addition, in non-endemic
areas, clinical or serological suspicions must almost always be conﬁrmed by culture (and or PCR) and/or BST.
(g): In zones where subcutaneous S19 or Rev.1 vaccination is practiced, NH test may help in differentiating antibodies due to
vaccination from those due to infection. In free countries or zones affected by the FPSR, both NH and cytosol-based tests
are suitable for differentiating FPSR from true infections.
(h): Dairy cattle only.
(i): NH tests particularly useful for testing and slaughtering purposes when adult vaccination with S19 (cattle) or Rev 1 (small
ruminants) is performed. Cytosol-protein based tests particularly useful when false positive serological reactions occur.
(j): Of limited efﬁcacy when testing pigs.
(k): The best selective culture media are the Farrell’s and CITA’s media (see De Miguel et al., 2011); PCR: polymerase chain
reaction; BBAT: buffered Brucella antigen tests (i.e. Rose Bengal test (RBT) and buffered plate agglutination test (BPAT)).
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humans (Spink et al., 1962; Ashford et al., 2004). Another disadvantage of RB51 is that it is resistant to
rifampicin, which is often used for treating brucellosis (Gulsun et al., 2011).
Large-scale Rev.1 vaccination programmes proved its capacity to reduce the Brucella
seroprevalence (Ward et al., 2012; SCOFCAH, 2011). On the other hand, Brucella has been
occasionally detected in milk of Rev.1-vaccinated goats (Banai, 2002), the vaccine strain is virulent to
humans (Blasco and Diaz, 1993) and differentiating naturally infected with B. melitensis and B. ovis
from Rev.1-vaccinated animals might be difﬁcult in vaccine is applied subcutaneously or in adults
(Fensterbank et al., 1982).
The general characteristics of the currently available vaccines for the prophylaxis of animal
brucellosis are summarised in Table 5.
Table 5: General characteristics of currently available brucellosis vaccines (Adapted from Blasco
et al. (2016))
Vaccine Advantages Disadvantages Comments
B. melitensis
Rev.1
Proved efﬁcacy in control/
eradication programmes
(France, Italy, Portugal,
Spain)
Effective against both
B. melitensis and B. ovis
Safe in young
replacements (males and
females)
Single dose affords useful
protection for life
Biological quality control
feasible (OIE protocol)
Highly abortifacient when used in
pregnant animals
Serological interference in classical
serological tests (RBT, CFT),
indirect and competitive ELISAs,
ﬂuorescence polarisation assay,
and other S-LPS tests
Low virulence for humans;
streptomycin resistant
Safety issues minimised by
avoiding use in mid-pregnancy
animals by the conjunctival route
Serological interference is
minimised when applied to
young replacements by the
conjunctival route
Human infections can be
diagnosed using standard
serological tests; treatment
requires regimes that do not
include streptomycin
B. abortus
S19
Proved efﬁcacy in control/
eradication programmes
(EU countries, USA and
Australia)
Protects cattle against
both B. abortus and
B. melitensis
Single dose affords useful
protection for life
Biological quality control
feasible (OIE protocol)
Depending on the dose and
vaccination route can be
abortifacient when used in
pregnant cattle
Used subcutaneously is not safe in
bulls (unknown when applied by
the conjunctival route)
Serological interference in classical
serological tests (RBT, CFT),
indirect and competitive ELISAs,
ﬂuorescence polarisation assay,
and other S-LPS tests
Low virulence for humans
Serological interference is
minimised when reduced doses
are applied to young animals
(particularly by the conjunctival
route)
Abortive effect minimised when
reduced doses are applied by the
conjunctival route
Human infections can be
diagnosed using standard
serological tests; standard
antibiotic treatment effective
B. abortus
RB51
• No interference in
classical serological
tests (RBT, CFT)
• Not recommended in
pregnant cattle
(abortifacient) or bulls.
• Less effective than S19 in
inducing protective immunity
(efﬁcacy or revaccination
unknown).
• Unknown protection span.
• Protection of cattle against
B. melitensis unknown.
• Serological interference in
indirect and competitive
ELISAs and ﬂuorescence
polarisation assay.
• Low virulence for humans;
rifampicin resistant
• No proved efﬁcacy for
eradication.
• No appropriate serological
diagnostic tests to
diagnose human
infections; treatment
requires regimes that do
not include rifampicin
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B. suis
With the exception of a live attenuated Chinese vaccine (Xin, 1986), whose efﬁcacy for brucellosis
has been disproven in controlled experiments in ruminants (Bosseray and Plommet, 1990; Blasco
et al., 1993; Verger et al., 1995), no vaccines are available against brucellosis in pigs.
Parameter 2 – Availability/production capacity (per year)
The three vaccines currently available are widely produced worldwide with important regional
differences.
In the EU, the production capacity of the S19 vaccine is limited (only three manufacturing
companies exist in Spain), as it is also the case of RB51 (only one company exists in Spain). In the
case of B. melitensis Rev.1 vaccine, the situation is similar with a single manufacturing company in
France (Hungary) and three more companies in Spain. Italy produces also a reduced amount of Rev.1
manufactured by a single ofﬁcial laboratory but not by private companies. As a consequence of the
effective control/eradication of brucellosis in the EU MS, these manufacturing companies have reduced
signiﬁcantly the overall production capacity, which is essentially maintained for the export market.
However, manufacturing technology is currently well implemented and the production capacity of these
remaining companies could be signiﬁcantly increased to cover an emergency situation, at least at
medium term.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
B. abortus S19 and B. melitensis Rev.1 remain the most effective vaccines, and when combined
with test and slaughter have been instrumental in almost all successful cases of eradication. A single
dose of these vaccines confers from 50% to 100% protection against challenges infecting 80–100% of
unvaccinated controls (Nicoletti, 1990; Jacques et al., 2007; Barrio et al., 2009; Dorneles et al., 2015).
However, quality of product is essential and thus there are internationally accepted quality control
protocols for both vaccines (Grillo et al., 2000; OIE, 2016).
Although RB51 vaccine also protects cattle against mild B. abortus challenges (Moriyon et al., 2004;
Dorneles et al., 2015), the protective life span of this vaccine is unknown, and ﬁeld infections in
vaccinated animals have been observed even in revaccinated cattle (Moriyon et al., 2004; Herrera-
Lopez et al., 2010). Under controlled conditions, the few valid comparisons strongly suggest that RB51
is inferior to S19 (Moriyon et al., 2004).
Whether RB51 protection is useful under ﬁeld conditions has been a matter of debate.
Parameter 4 – Duration of protection
It has been proven experimentally that Rev.1 induces suitable protection against B. melitensis in
sheep for at least two consecutive pregnancies (Verger et al., 1995). The protection lapse span of
Rev.1 against B. melitensis in goats is very long at 4–5 years (Alton, 1990; Dıaz-Aparicio et al., 2004).
The duration of immunity induced by S19 in cattle vaccinated as calves has been proven to be also
quite long, covering almost the entire productive lifespan of the animals, and it has been reported that
the immunity in cattle vaccinated between 6 and 8 months of age does not decrease from the ﬁrst
through the ﬁfth pregnancy (Dorneles et al., 2015). Revaccination with S19 demonstrated no apparent
beneﬁt in cattle and as in the case of the Rev.1 vaccine, a single vaccination is considered effective
enough for the whole productive lifespan of the animals (Dorneles et al., 2015).
The protective lapse span of RB51 vaccine is unknown.
3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
For economic, epidemiological and public health reasons, treatment with antibiotics has been generally
precluded in animals infected with brucellosis. However, several therapeutic regimens have been
evaluated successfully for brucellosis in cattle, sheep, pigs and dogs (Nicoletti et al., 1985; Marın et al.,
1989; Jimenez de Bag€ues et al., 1991; Grillo et al., 2006; Dieste et al., 2011; Dieste-Perez et al., 2014).
The therapeutic effect has been reported as 67% using oxytetracycline combined with
streptomycin, and as approximately 20% using oxytetracycline alone (Nicoletti et al., 1985).
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3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 - Available biosecurity measures
Brucellosis is mainly spread through:
• animals moving between and within farms and, in particular, the introduction of new animals
with unknown or poorly certiﬁed ofﬁcially free status (the entry of latent carriers in particular);
• direct contact with neighbours’ animals/farms infected with brucellosis;
• sharing equipment, feed, water and bedding between farms;
• direct contacts with wildlife (relevant in the case of porcine brucellosis due to B. suis biovar 2).
Measures avoiding these risk factors should contribute to minimise brucellosis spread between
infected and healthy herds/ﬂocks. Biosecurity would be focused essentially on controlling and reducing
movements of animals (particularly the purchase of replacements avoiding latent carriers), feed, water,
people and equipment to and from areas where livestock is kept.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
While the above measures are feasible and effective for minimising brucellosis spread in highly
intensiﬁed farming systems (usually ruminant dairy herds/ﬂocks and swine reared intensively), they are
very difﬁcult to implement in outdoor or fully extensive/transhumant breeding systems, in particular for
preventing porcine brucellosis. In the case of brucellosis in domestic ruminants, and at least in the EU,
rules on zoning and on restriction of animal movements according the available EU Directives, have
been proven very effective to minimise the spread of B. abortus and B. melitensis infections.
In contrast, biosecurity measures minimising the spread of porcine brucellosis due B. suis biovar 2
in the EU are very difﬁcult (if not impossible) to implement. As this infection is widespread in wildlife,
the only feasible biosecurity measures are: (i) reducing the wildlife density and (ii) avoiding the
contacts between wildlife and domestic swine though suitable fencing (EFSA, 2009).
Feasibility
Parameter 3 – Feasibility of biosecurity measures
Biosecurity measures for avoiding the spread of B. abortus and B. melitensis infections in domestic
ruminants based on the current rules on zoning and on restriction of animal movements according the
available EU Directives, have been proven feasible and very effective.
However, biosecurity measures minimising the spread of porcine brucellosis due B. suis biovar 2 in
the EU are very difﬁcult (if not impossible) to implement. Reducing the density of wild boar (the main
reservoir of infection) can be attempted but results are uncertain given the high capacity for
movements of these wild animals. The total depopulation of wild reservoir species seems neither
feasible nor ethically justiﬁed. The most effective way to prevent contacts between wild boar and
domestic pigs is a suitable fencing system (EFSA, 2009). However, while this suitable (usually very
expensive) fencing is feasible for some particular backyard farms and industrial outdoor breeding
holdings, it cannot be implemented in fully extensive systems like those typical for Iberian pigs in the
Iberian Peninsula and other similar outdoor pig breeding systems.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
Council Directive 64/432/EEC3, Council Directive 91/68/EEC4 and Commission Decisions lay down
conditions applying to imports of live animals and products from third countries. The SPS Agreement
recognises the OIE as the relevant international organisation responsible for the development and
promotion of international animal health standards, guidelines, and recommendations affecting trade in
3 Council Directive 64/432/EEC of 26 June 1964 on animal health problems affecting intra-Community trade in bovine animals
and swine. OJ 121, 29.7.1964, p. 1977–2012.
4 Council Directive 91/68/EEC of 28 January 1991 on animal health conditions governing intra-Community trade in ovine and
caprine animals. OJ L 46, 19.2.1991, p. 19–36.
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live animals and animal products. These internationally accepted rules are contained in the OIE
Terrestrial Animal Health Code (http://www.oie.int/en/international-standard-setting/terrestrial-code/
access-online/).
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
The existing EU Directives on the restriction of movements have proven to be highly effective in
preventing the spread of brucellosis between farms in the MS in which the disease yet exists. However,
these rules allow that animals born from infected dams but showing false negative results in the
ofﬁcial tests and that may be latently infected may qualify for OBF status. To avoid this possibility, MS
currently involved in the EU ofﬁcial eradication programmes state generally require animals born from
infected dams to be also culled in the infected holdings that are not submitted to full depopulation.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
The Council Directives dealing with restrictions of animal movement (see Parameter above) have
been successfully implemented by MS many years ago, and have proven to be of paramount
importance in the successful eradication of brucellosis and to reduce the spread of the disease in the
countries in which the disease is yet present. Accordingly, these measures have a wide acceptance in
the EU MS and have been proven feasible. Computerised management of livestock movements
constitutes a further step in the management of health hazards associated with the movement of
animals. To facilitate such control, the EU require national computerised registers containing basic
details about any national movement of animals and, in some cases, international movement.
Furthermore, the Trade Control and Expert System (TRACES) has been widely implemented in EU MS.
This is an on-line system which comprises a network of Veterinary Authorities and economic operators
of Member States (Commission Decision 2003/623/EC5).
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
Brucellosis eradication requires the identiﬁcation of infected animals, their progressive elimination
from the herd/ﬂock and replacement with non-infected animals (Crespo Leon et al., 2012). Council
Directives 64/432/EEC (amended and updated) – for bovines – and 91/68/EEC – for sheep and goats –
establish the procedures for gaining, maintaining, suspending, withdrawing or regaining the OBF status
in the EU. The culling of infected animals (and even the full depopulation of the affected herd/ﬂock) is
properly stated and justiﬁed in both Directives, and this has been a tool of critical importance for the
successful eradication of brucellosis in some MS, as well as for the signiﬁcant reduction of spread in
those MS in which brucellosis yet exists.
In the case of identifying and conﬁrming B. suis infection in holdings belonging to MS, the
slaughter of infected pigs is recommended. However, in these cases it is more advisable to adopt
whole-herd depopulation (the measure currently applied in the few cases in which B. suis outbreaks
have been conﬁrmed in EU MS) as this would reduce the risk of spread to other holdings (EFSA,
2009).
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing /stopping
spread of the disease
The killing of infected animals or the whole depopulation of infected holdings has been successfully
implemented in EU MS for many years, and proven to be of paramount importance in the successful
eradication of brucellosis in some MS as well as to reduce the spread of the disease in MS in which the
disease is still present.
5 2003/623/EC: Commission Decision of 19 August 2003 concerning the development of an integrated computerised veterinary
system known as Traces. OJ L 216, 28.8.2003, p. 58–59.
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Feasibility
Parameter 3 – Feasibility of killing animals
These measures have a wide acceptance in the EU and have been proven effective and feasible
after many years of application.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
At the EU level, the killing of infected animals (or the whole herd/ﬂock) can be made by several
procedures, all proven feasible and effective after many years of application of the ofﬁcial eradication
programmes. The slaughter of infected animals/whole holdings can be made at ﬁeld level in the
affected holding or, alternatively, in selected places authorised for this purpose. Once killed, the
animals have to be sent to authorised disposal centres, according the rules stated in Regulation (EC)
No 1069/20096. Alternatively, the infected animals (or the whole herd/ﬂock affected) can be sent to
specially authorised slaughterhouses, and the carcasses can be authorised for human consumption
according the rules described in Regulations (CE) No 853/20047 and (EC) No 854/20048. In the EU
Food Law, brucellosis in animals is listed as a speciﬁc hazard and detailed provisions for the disease to
ensure safety of meat and to protect public health have been established therein. Chapter IX (F) of
Section IV of Annex I to Regulation (EC) No 854/2004 lays down speciﬁc rules for the organisation of
ofﬁcial controls on products of animal origin intended for human consumption.
Effectiveness
Parameter 2 – Effectiveness of disposal option
The above options have been successfully applied by EU MS for many years and proven safe and
effective enough for the disposal of brucellosis infected animals/holdings.
Feasibility
Parameter 3 – Feasibility of disposal option
The above options have been successfully applied in EU MS for many years, and proven feasible for
the disposal of brucellosis infected animals/holdings.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
There are very few well-documented studies on the production losses and the economic impact of
brucellosis taking into account all aspects of the disease. In particular, little is known about how
brucellosis affects animal production quantitatively, and the ﬁgures used as a reference were
established empirically many years ago (Bernues et al., 1997). Moreover, well-documented studies on
the indirect costs of brucellosis are also scarce. A review of the studies available concludes that
brucellosis is in all likelihood a major problem in low-income countries of Africa and Asia (McDermott
et al., 2013).
An overall brucellosis framework that considers costs of illness, costs of prevention, and opportunity
costs (both public and private) at household, livestock sector, health sector and broader societal levels
is shown in Table 6.
It can be concluded that the cost estimates published for brucellosis are of limited value.
6 Regulation (EC) No 1069/2009 of the European Parliament and of the Council of 21 October 2009 laying down health rules as
regards animal by-products and derived products not intended for human consumption and repealing Regulation (EC)
No 1774/2002 (Animal by-products Regulation). OJ L 300, 14.11.2009, p. 1–33.
7 Regulation (EC) No 853/2004 of the European Parliament and of the Council of 29 April 2004 laying down speciﬁc hygiene
rules for food of animal origin. OJ L 139, 30.4.2004, p. 55–205.
8 Regulation (EC) No 854/2004 of the European Parliament and of the Council of 29 April 2004 laying down speciﬁc rules for the
organisation of ofﬁcial controls on products of animal origin intended for human consumption. OJ L 139, 30.4.2004, p. 206–320.
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Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
In rich countries, an important part of successful brucellosis eradication has been the ofﬁcial
compensations given to farmers for the culled livestock. However, in high prevalence conditions and in
most resource-limited countries, eradication is not feasible, and applying control programmes is the
only suitable option (Blasco and Molina-Flores, 2011). To attempt control (usually through mass
vaccination of the whole susceptible population), the beneﬁts to public health and society need to be
demonstrated, particularly in countries with limited resources. The costs of these control programmes
are highly variable and depend essentially of the country, the animal species involved, the vaccination
programme selected (for a review see Blasco and Molina-Flores (2011) and Blasco et al. (2016)), and
the vaccine used. Accordingly, well-documented economic analyses of brucellosis control programmes
are also scarce.
An interesting cost-beneﬁt study of a control programme based on vaccination of small ruminants
with the Rev.1 vaccine was conducted in Portugal (Coelho et al., 2011). The most relevant costs saved
and expensed when applying a mass-vaccination programme with Rev.1 are shown in Table 7.
Table 6: Costs to be considered and estimated when planning brucellosis control and eradication
programmes (McDermott et al., 2013)
Actors Cost of illness Cost of prevention
Intangible and
opportunity costs
Private Individuals and
households
Treatment (e.g.
medication), loss of
household production
Risk mitigation (e.g.
boiling milk)
Disutility of ill health per
individual (DALYs)
Disutility of ill health for
friends, family, etc.
Livestock sector Treatment, herd
slaughter, market loss
due to risk of infected
meat and milk, mortality,
morbidity, lower
production, loss of
exports
Biosecurity, vaccination*
and procedures to control
disease along the value
chain (e.g. pasteurisation) Future emerging disease
Loss of animal genetic
resources
Loss of opportunities
occasioned by spending on
disease prevention and
cure
Public Health sector
(human and
animal)
Treatment (hospital
provision, etc.)
Outbreak costs,
movement restrictions,
culling, vaccination
Risk mitigation (e.g.
movement control and
vaccination*), disease
surveillance, research
Economy Indirect effects on
economic development,
ecosystem services and
tourism
Biosecurity, avoiding
wildlife and vectors,
disease surveillance,
research
Dark grey boxes: market prices available and commonly included in economic assessments of disease. Light grey boxes: market
prices not available so costs need to be estimated through other methods. White boxes: prevention costs reﬂect efﬁciency and
effectiveness of public and private service provision. Usually there are few data and only rough estimates are made. Black box:
included in health metrics (DALYs: disability-adjusted life years).
*: A number of costs (for example, vaccination) produce beneﬁts for both the private sector (better livestock production) and the
public sector (fewer human infections).
Table 7: Total incremental costs in US$ for Brucella control using a strategy based on mass vaccination
of small ruminant with Rev.1 vaccine in Tras-os-Montes e Alto Douro (2000–2005), Portugal
(Coelho et al., 2011)
Difference
between
the years
Compensation costs
paid to farmers
Vaccine costs
Cost of patient
hospitalisation
Total
Spent Saved Spent Saved Spent Saved Spent Saved
2000–2001 115,357 – 19,592 – – 24,451 110,498 –
2000–2002 – 331,148 29,843 – – 89,411 – 390,716
2000–2003 – 1,069,300 39,681 – – 206,507 – 1,236,125
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In the ﬁve years of study, more than US$ 3,000,000 were saved after mass vaccination with Rev.1
with respect to the costs generated by an eradication programme (consisting in the vaccination of only
young replacements and testing and culling the adult sheep and goats) with an annual average
reduction in monetary costs of US$ 603,714. The annual average saving in costs of compensation paid
to farmers and cost of patient hospitalisation in hospitals were US$ 515,400 and US$ 100,471,
respectively (Coelho et al., 2011).
Parameter 2 – Cost of eradication (culling, compensation)
Due to the important variations in the prevalence and in the costs of diagnostic tools/vaccines and
of the operative costs of the involved private/public veterinary services in the different countries, no
internationally recognised costs have been deﬁned for eradication, monitoring and surveillance.
However, precise ﬁgures, updated yearly and available on line (http://ec.europa.eu/dgs/health_food-
safety/funding/cff/animal_health/index_en.htm, exist in the case of EU MS in which brucellosis is yet
present.
Sheep and goats
As an example, the costs of the eradication programme for brucellosis in small ruminants submitted
to the EU by Portugal (http://ec.europa.eu/dgs/health_food-safety/funding/cff/docs/animal_vet-progs_
2016-7_dec-2015-3609-ec_ov-cap-brucellosis_prt.pdf) are for year 2016 €2,394,916. This was
calculated considering the following relevant ﬁgures: 60,452 ﬂocks to be tested, 0.62% expected
collective (ﬂock) prevalence, 2,193,200 animals to be tested, 0.1% expected individual prevalence, and
48,830 animals to be vaccinated with the Rev.1 vaccine.
Cattle
The total cost of the brucellosis eradication programme to be carried out in bovines in Italy for year
2016 is €11,219,302. This was calculated considering the following relevant ﬁgures: 33,822 ﬂocks to
be tested, 0.71% expected collective (herd) prevalence, 1,004,279 animals to be tested, and 0.37%
expected individual prevalence.
Between 2007 and 2011, the total cost incurred by the Health Service of Lazio Region (Italy) for
the eradication of brucellosis in cattle was estimated in 5,996.809 EUR, of those 4,797,389 were the
cost of the veterinarians labour, 8,864 for the transport, 23,908 for disposal and compensation for
culled animals (Caminiti et al., 2016).
Parameter 3 – Cost of surveillance and monitoring
See above.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
See next Parameter.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
Economic losses due to a serious and unexpected brucellosis outbreak occurring in an ofﬁcially free
MS could be large and widespread if no ofﬁcial intervention is conducted. First, losses would include
the value of lost production, the cost of destroying diseased or potentially diseased animals, and the
costs of containment (diagnostics, compensation to producers for destroyed animals, disposal costs
and costs of veterinary services). Second, and very important, export markets could be lost if
importing countries place restrictions on products to prevent the possibility of disease spread. Third,
multiplier effects could ripple through the economy due to decreased sales by agriculturally dependent
businesses (farm input suppliers, food manufacturing, transportation, retail grocery, and food service).
Difference
between
the years
Compensation costs
paid to farmers
Vaccine costs
Cost of patient
hospitalisation
Total
Spent Saved Spent Saved Spent Saved Spent Saved
2000–2004 – 1,870,307 55,826 – – 341,399 – 2,155,879
2000–2005 – 2,577,002 60,788 – – 502,356 – 3,018,569
Mean/year – 515,400 12,158 – – 100,741 – 603,714
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Finally, as brucellosis is a zoonosis, tourism could be affected also if negative perceptions for food or
personal safety exist. Depending on the erosion of consumers’ conﬁdence and export sales, market
prices of the affected commodities (essentially live animals and meat) may drop. This would affect not
only to the owners of the affected area but also to producers whose herds were not directly infected,
making the event national in scale even if the disease itself is contained to a small region.
Fortunately, the expected impact of a brucellosis outbreak in a given ofﬁcially free MS in the current
epidemiological situation should not be very high due to the existence of zoning or regionalisation in
the EU, and the continuous surveillance of the brucellosis free areas, allowing an early response in the
eventual detection of any brucellosis outbreak. Zone/region means a clearly deﬁned part of a country
containing an animal subpopulation with a distinct health status with respect to a speciﬁc disease
(brucellosis in this case) for which required surveillance, control and biosecurity measures have been
applied for trade purposes. Accordingly, the EU deﬁnes clearly and regularly the MS regions with the
different brucellosis status inside the national boundaries for the purposes of international trade or
disease control strategies. Having in consideration the favourable evolution of brucellosis even in the
MS in which infection persists, and the epidemiological nature of brucellosis (low capacity of spreading
at the short term), any unexpected local brucellosis outbreak should not have important consequences
for the sector if interventions are applied over a short period. An exception could be porcine brucellosis
since the EU is the main exporter of swine/swine meat to the international markets (around 37% of
the total exports worldwide). If trade were limited by third countries, the consequences for the EU
swine industry could be very important.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
Consumer conﬁdence in government may be tested depending on the scale of the eradication effort
and the means used for the disposal the animals culled. The need to slaughter thousands of animals
could generate public criticism if culling methods are considered inhumane or if the destruction of
carcasses is questioned environmentally. This should thus be avoided. Fortunately, the currently
applied culling and disposal systems used in the EU eradication programmes for brucellosis have been
widely accepted by the affected owners and the society in general.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Whenever properly managed by competent veterinarians, the measures implemented for controlling
brucellosis (usually through vaccination), do not pose a relevant issue from the animal welfare
standpoint.
Parameter 2 – Wildlife depopulation as control measure
This is not an issue in the case of B. abortus and B. melitensis infections since wild animals are
very rarely affected and, in the case of sporadic infections, this does not have any epidemiological
signiﬁcance. In the very rare event that high prevalence of these infections is found in wildlife (i.e. the
case of the Alpine Ibex infected by B. melitensis in a very restricted area of the French Alps (Mick
et al., 2014), the depopulation of the affected wild animals could be considered whenever this be
feasible, socially acceptable, and the animal species involved is not endangered.
In contrast, this could be considered in the case of the infection caused by B. suis biovar 2 since
both wild boar and hares are the wild reservoir of porcine brucellosis in the EU and the prevalence is
very high in both species (EFSA, 2009; Mu~noz et al., 2010). The precise role played by hares in the
transmission of infection to swine remains unclear (EFSA, 2009). However, available evidence suggests
that wild boar is the main source of infection for domestic pigs bred in outdoor rearing systems, even
on fenced premises (EFSA, 2009; Mu~noz et al., 2010). This outdoor housing is used in open air semi-
intensive systems or in extensive systems (as the free ranging Iberian pig system), which have a
moderate to high but permanent risk of infection via contacts with infected wild boar (EFSA, 2009;
Mu~noz et al., 2010). As full depopulation of wild boar in the EU is unfeasible, reducing the population
density of wild boar could be a suitable alternative to reduce the risk of transmission of B. suis biovar
2 to domestic pigs reared in these outdoor breeding systems.
AHL assessment on the infection with Brucella abortus, B. melitensis and B. suis
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2017;15(7):4889
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
No drugs/chemicals other than the common and legally accepted disinfectants are used in the
current control/eradication campaigns in the EU.
Biodiversity
Parameter 2 – Mortality in wild species
Wild animals are not affected signiﬁcantly by the disease in the EU, with the exception of B. suis
biovar 2 affecting wild boar and hares. However, brucellosis is a non-fatal disease for wildlife and
domestic animals.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about the infection with B. abortus, B. melitensis and B. suis (Table 8). The expert judgement was
based on Individual and Collective Behavioural Aggregation (ICBA) approach described in detail in the
opinion on the methodology (EFSA AHAW Panel, 2017). Experts have been provided with information
of the disease fact-sheet mapped into Article 5 criteria (see supporting information, Annex A), based
on that the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 5, and the
reasoning supporting their judgement.
The minimum number of judges in the judgement was 10. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 8: Outcome of the expert judgement on the Article 5 criteria for the infection with
Brucella abortus, B. melitensis and B. suis
Criteria to be met by the disease: According to AHL, a disease shall be included in the list
referred to in point (b) of paragraph 1 of Article 5 if it has been assessed in accordance with
Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist
in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease: In addition to the criteria set out above at point A(i)-A(v),
the disease needs to fulﬁl at least one of the following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger to
public and/or animal health in the Union
N
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
Y
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
N
Colour code: green = consensus (Yes/No).
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3.2.1. Outcome of the assessment of the infection with Brucella abortus,
B. melitensis and B. suis according to criteria of Article 5(3) of the AHL on
its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 8, the infection
with B. abortus, B. melitensis and B. suis complies with all criteria of the ﬁrst set and with three
criteria of the second set, therefore it is considered eligible to be listed as laid down in Article 5 of the
AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about the infection with B. abortus, B. melitensis and B. suis
(Tables 9, 10, 11, 12 and 13). The expert judgement was based on ICBA approach described in detail
in the opinion on the methodology. Experts have been provided with information of the disease
fact-sheet mapped into Article 9 criteria (see supporting information, Annex A), based on that the
experts indicate their Y/N or ‘na’ judgement on each criterion of Article 9, and the reasoning
supporting their judgement.
The minimum number of judges in the judgement was ten. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 9: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for the infection with Brucella abortus, B. melitensis and B. suis
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory of
the Union
N
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
At least one criterion to be met by the disease: In addition to the criteria set out above at point 1-2.4, the
disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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Table 10: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for the infection with Brucella abortus, B. melitensis and B. suis
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character
AND (at the same time) several Member States or zones of the Union are free of the disease
Y
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 the disease may result in high morbidity with in general low mortality Y
At least one criterion to be met by the disease: In addition to the criteria set out above at point 1-2.4, the
disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
Y
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 11: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for the infection with Brucella abortus, B. melitensis and B. suis
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
Y
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
Y
At least one criterion to be met by the disease: In addition to the criteria set out above at point 1-2.4, the
disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
Y
4 The disease has a signiﬁcant impact on the economy of the Union, mainly related to its
direct impact on certain types of animal production systems
N
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 14, 15
and 16). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different
supporting views for each answer.
Reasoning supporting the judgement
supporting Yes for 2.1 (cat.A):
• Within-herd animal prevalence rapidly reaches 30–100% when infection is ﬁrst introduced into
a herd or ﬂock.
• The infective dose is low and thus it is the most frequent and easily acquired zoonotic
occupational infection.
• Latency with negative serology and disease recrudescence during pregnancy are common and
responsible for many incidents of transmission to large numbers of animals.
• The estimation of R0 is not straightforward because transmission dynamics are complicated by
multiple interactions between animals.
• supporting Yes for 2.1 (cat.B,C):
• Published R (R0, Re) values are relatively low (less than 2 in most cases).
After discussion, the AHAW Panel reached consensus about the disease being at least moderately
transmissible.
Table 12: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for the infection with Brucella abortus, B. melitensis and B. suis
Criteria to be met by the disease: The disease needs to fulﬁl all of the following criteria
Final
outcome
The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of section 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 13: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for the infection with Brucella abortus, B. melitensis and B. suis
Diseases in category E need to fulﬁl criteria of section 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment (If a disease fulﬁls the criteria as in
Article 5, thus being eligible to be listed, consequently category E would apply.)
Y
Colour code: green = consensus (Yes/No).
Table 14: Outcome of the expert judgement related to criterion 2.1 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.1 (cat.A) The disease is highly transmissible NC 50 50 0
2.1 (cat.B,C) The disease is moderately to highly transmissible NC 50 50 0
Number of judges: 10; NC: non-consensus.
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Reasoning supporting the judgement
supporting Yes:
• The disease has a substantial impact in infected areas, as a consequence of abortion and infertility.
• The disease can affect all productions systems for each susceptible species.
• The loss of the ofﬁcially free status may have important economic consequences due to the
ban on trade of live animals for breeding or slaughter (breeders in particular) as well as
semen, embryos and raw-milk products (OIE code provisions).
supporting No:
• In the current situation and given the control measures in place in the EU, the impact is not
signiﬁcant on the economy of the whole Union due to actual low prevalence and incidence in MSs
(maximum 0.78% prevalence and 0.61% incidence in Italy in 2016 in small ruminants (expected).
Reasoning supporting the judgement
supporting Yes:
• Brucellosis is considered a major contributor to animal suffering, causing fever, abortions,
stillbirths and the birth of weak offspring, with the ensuing increase of perinatal mortality.
• It is present in more than in 3 countries.
supporting No:
• In the current situation and given the control measures in place in the EU, there is no welfare
impact on large number of animals because of the low prevalence.
3.3.2. Outcome of the assessment of criteria in Annex IV for the infection with
Brucella abortus, B. melitensis and B. suis for the purpose of
categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 9–13. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
A description of the outcome of the assessment of criteria in Annex IV for the infection with
B. abortus, B. melitensis and B. suis for the purpose of categorisation as in Article 9 of the AHL is
presented in Table 17.
Table 15: Outcome of the expert judgement related to criterion 4 of Article 9
Question*
Final
outcome
Response
Y (%) N (%) na (%)
4 (cat.A,B) The disease has a signiﬁcant impact on the economy of the
Union, causing substantial costs, mainly related to its direct
impact on the health and productivity of animals
NC 90 10 0
Number of judges: 10; NC: non-consensus.
*: At the time of the collective judgement, the assessment of the current impact considering the control measures in place was
considered.
Table 16: Outcome of the expert judgement related to criterion 5(b) of Article 9
Question*
Final
outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 70 30 0
Number of judges: 10; NC: non-consensus.
*: At the time of the collective judgement, the assessment of the current impact considering the control measures in place was
considered.
AHL assessment on the infection with Brucella abortus, B. melitensis and B. suis
www.efsa.europa.eu/efsajournal 33 EFSA Journal 2017;15(7):4889
According to the assessment here performed, the infection with B. abortus, B. melitensis and
B. suis complies with the following criteria of the sections 1–5 of Annex IV of the AHL for the
application of the disease prevention and control rules referred to in points (a) to (e) of Article 9(1):
1) For being assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment brucellosis complies with criteria 2.2, 2.3, but
not with 1, 2.1 and 2.4. For being eligible for category A, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and brucellosis does not
comply with criteria 3, 5a, 5c and 5d and the assessment is inconclusive on compliance with
criteria 4 and 5b.
2) For being assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment brucellosis complies with all criteria. For being
eligible for category B, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and brucellosis complies with criterion 3, does not comply with
criteria 5a, 5c and 5d and the assessment is inconclusive on compliance with criteria 4 and
5b.
3) For being assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment brucellosis complies with all criteria. For being
eligible for category C, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and brucellosis complies with criterion 3, does not comply with
criteria 4, 5a, 5c and 5d and the assessment is inconclusive on compliance with criterion 5b.
4) For being assigned to category D, a disease needs to comply with criteria of section 1, 2, 3
or 5 of Annex IV of the AHL and with the speciﬁc criterion D of section 4, which brucellosis
complies with.
5) For being assigned to category E, a disease needs to comply with criteria of section 1, 2 or
3 of Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons
relating to animal health, animal welfare, human health, the economy, society or the
environment. The latter is applicable if a disease fulﬁls the criteria as in Article 5, which
brucellosis complies with.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
the infection with B. abortus, B. melitensis and B. suis. The Article 8(3) criteria are about animal
species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
Table 17: Outcome of the assessment of criteria in Annex IV for the infection with Brucella abortus,
B. melitensis and B. suis for the purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1°set of criteria 2°set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.9 According to the
mapping, as presented in Table 5, section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for the infection with B. abortus,
B. melitensis and B. suis according to the criteria of Article 8(3) of the AHL are as displayed in
Tables 18 and 19.
Table 18: Animal species to be listed for the infection with Brucella abortus and B. melitensis
according to criteria of Article 8 (source: data reported in Section 3.1.1.1)
Order Family Genus/species
Susceptible Artiodactyla Camelidae Camelus dromedarius, Camelus bactrianus, Lama glama,
Vicugna pacos, Lama guanicoe, Vicugna vicugna
Cervidae Cervus elaphus, Alces alces
Suidae Sus scrofa
Bovidae Bos taurus, Bubalus bubalis, Bison bonasus, Bison bison,
Bos grunniens, Syncerus caffer, Capra hircus, Ovis aries,
Capra ibex, Rupicapra spp., Capra pyrenaica, Kobus leche
kafuensis, Hippotragus niger, Oryx leucoryx
Carnivora Canidae Canis lupus, Canis latrans, Vulpes vulpes
Procyonidae Procyon lotor
Didelphimorphia Didelphidae Not speciﬁed
Perissodactyla Equidae Equus caballus
Reservoir Artiodactyla Bos taurus (B. abortus) Ovis aries, Capra hircus
(B. melitensis)
Vectors None
Table 19: Animal species to be listed for the infection with Brucella suis according to criteria of
Article 8 (source: data reported in Section 3.1.1.1)
Order Family Genus/species
Susceptible Artiodactyla Suidae Sus scrofa
Bovidae Not speciﬁed
Cervidae Rangifer tarandus
Tayassuidae Peccaries (all genera)
Perissodactyla Equidae Equus caballus
Carnivora Canidae Vulpes lagopus, Canis lupus
Rodentia Not speciﬁed
Lagomorpha Leporidae Lepus europaeus
Reservoir Artiodactyla Suidae Sus scrofa (biovars 1, 2 and 3)
Tayassuidae Peccaries (all genera) (biovars 1 and 3)
Cervidae Rangifer tarandus (biovar 4)
Rodentia Small rodents (several species) (biovars 2 and 5)
Vectors None
9 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, the infection with B. abortus, B. melitensis and
B. suis complies with all criteria of the ﬁrst set and with three criteria of the second set and
therefore can be considered eligible to be listed for Union intervention as laid down in Article 5(3)
of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, the infection with B. abortus, B. melitensis and
B. suis meets the criteria as in sections 2, 3, 4, and 5 of Annex IV of the AHL, for the
application of the disease prevention and control rules referred to in points (b), (c), (d), and
(e) of Article 9(1) of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for the infection with B. abortus, B. melitensis and B. suis according to Article 8(3) of the
AHL are several mammal species, as reported in Tables 18 and 19 in Section 3.4 of the
present document.
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Appendix A – Tables
Table A.1: Diagnostic sensitivity (DSe) and speciﬁcity (DSp) of serological tests for the diagnosis of
B. melitensis infection in sheep (n.d.: not determined)
Tests
% DSe (no.
tested) [95%
CI] with sera
from
%DSp (no. tested) [95% CI]
with sera from
Brucella
infected
Brucella free
% DSp (no. animals/age in
months at /months post-Rev 1
vaccination) [95% CI] Reference
Conjunctival
route
Subcutaneous
route
stRBT 85.9 (135)
[80.0–91.8]
100 (416)
[98.9–100]
n.d. n.d. Blasco et al.
(1994a)
100 (77)
[94.1–100]
100 (77)
[94.1–100]
90.9 (11/3/4)
[57.1–99.5]
0.0 (11/3/4)
[0–32.1]
Jimenez de
Bag€ues et al.
(1992)90.0 (10/13/4)
[54.1–99.5]
10.0 (10/13/4)
[5.2–45.9]
mRBT 88.1 (135)
[82.7–93.6]
100 (416)
[98.9–100]
n.d. n.d. Blasco et al.
(1994a)
94.0 (135)
[90.0–98.0]
100 (55)
[91.9–100]
100 (60)
[92.5–100]
81.8 (11/3/4)
[47.8–96.8]
38.9 (18/3/6)
[18.3–63.9]
Marın et al.
(1999)
66.0 (56/14/5)
[52.1–77.8]
14.9 (47/14/5)
[6.7–28.9]
BPAT 77.5 (71)
[65.7–86.2]
99.8 (1,286)
[99.3–99.9]
n.d. n.d. Nielsen and Gall
(2001)
CFT 92 (55)
[81.6–97.6]
100 (60)
[92.5–100]
100.0 (11/3/4)
[67.9–100]
77.8 (18/3/6)
[51.9–92.6]
Marın et al.
(1999)
69.6 (56/14/5)
[55.7–80.8]
44.7 (47/14/5)
[30.5–59.8]
83.1 (71)
[71.9–90.6]
99.5 (1,286)
[98.9–99.8]
n.d. n.d. Nielsen and Gall
(2001)
100 (77)
[94.1–100]
100 (77)
[94.1–100]
100 (11/3/4)
[67.9–100]
0.0 (11/3/4)
[0–32.1]
Jimenez de
Bag€ues et al.
(1992)60.0 (10/13/4)
[27.4–86.3]
60.0 (10/13/4)
[27.4–86.3]
iELISA -S/LPS 100 (140)
[96.7–100]
100 (100)
[95.4–100]
n.d. n.d. Blasco et al.
(1994b)
100 (55)
[91.9–100]
100 (60)
[92.5–100]
72.7 (11/3/4)
[39.3–92.7]
11.1 (18/3/6)
[1.9–36.1]
Marın et al.
(1999)
32.1 (56/14/5)
[20.6–46.1]
10.6 (47/14/5)
[4.0–23.9]
100 (77)
[94.1–100]
100 (77)
[94.1–100]
100.0 (11/3/4)
[67.9–100]
54.6 (11/3/4)
[24.6–81.9]
Jimenez de
Bag€ues et al.
(1992)90.0 (10/13/4)
[54.1–99.5]
80.0 (10/13/4)
[44.2–96.4]
93.0 (71)
[83.7–97.4]
97.6 (1,286)
[96.6–98.3]
Nielsen and Gall
(2001)
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Tests
% DSe (no.
tested) [95%
CI] with sera
from
%DSp (no. tested) [95% CI]
with sera from
Brucella
infected
Brucella free
% DSp (no. animals/age in
months at /months post-Rev 1
vaccination) [95% CI] Reference
Conjunctival
route
Subcutaneous
route
cELISA-S/LPS 96 (55)
[86.4–99.4]
100 (60)
[92.5–100]
89.5 (11/3/4)
[57.1–99.5]
88.9 (18/3/6)
[63.9–98.1]
Marın et al.
(1999)
89.3 (56/14/5)
[77.4–95.6]
87.2 (47/14/5)
[73.6–94.7]
76.1 (71)
[64.2–85.1]
99.7 (1,286)
[99.1–99.9]
n.d. n.d. Nielsen and Gall
(2001)
FPA 91.5 (71)
[81.9–96.5]
98.6 (1,286)
[97.8–99.1]
n.d. n.d. Nielsen and Gall
(2001)
GD-NH 90 (55)
[77.4–95.6]
100 (60)
[92.5–100]
100.0 (11/3/4)
[67.9–100]
100.0 (18/3/6)
[78.1–100]
Marın et al.
(1999)
96.4 (56/14/5)
[86.6–99.4]
85.1 (47/14/5)
[71.1–93.3]
RID-NH 96.1 (77)
[88.3–99.0]
100 (77)
[94.1–100]
100 (11/3/4)
[67.9–100]
81.8 (11/3/4)
[47.8–96.8]
Jimenez de
Bag€ues et al.
(1992)90.0 (10/13/4)
[54.1–99.5]
80.0 (10/13/4)
[44.2–96.4]
Table A.2: Diagnostic sensitivity (DSe) and speciﬁcity (DSp) of serological tests for the diagnosis of
brucellosis in cattle (n.d.: not determined)
Tests
% DSe (no.
tested) [95%
CI] with sera
from
%DSp (no. tested) [95% CI] with sera from
Brucella
infected
Brucella free
S19 vaccinated
(no. calves/
months after
vaccination)
[95% CI]
Reference
Affected by
FPSR (data
from Mu~noz
et al. 2004)
stRBT 100 (112)
[95.9–100]
100 (95)
[95.2–100]
n.d. Dıaz-Aparicio et al.
(1993)
n.d.
BPAT 97.8 (636)
[96.2–98.7]
98.7 (1,446)
[97.9–99.2]
48.7 (261/n.d.)
[42.5–54.9]
Nielsen et al. (1995) n.d.
n.d. n.d 50 (56/4)
[36.5–63.5]
Lord and
Cherwonogrodzky
(1992)
n.d.
SAT 81.5 (146)
[74.1–87.3]
98.9 (995)
[98.0–99.4]
n.d. McGiven et al.
(2003)
n.d.
n.d. n.d. 81 (56/4)
[67.2–89.3]
Lord and
Cherwonogrodzky
(1992)
n.d.
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Tests
% DSe (no.
tested) [95%
CI] with sera
from
%DSp (no. tested) [95% CI] with sera from
Brucella
infected
Brucella free
S19 vaccinated
(no. calves/
months after
vaccination)
[95% CI]
Reference
Affected by
FPSR (data
from Mu~noz
et al. 2004)
CFT 91.8 (146)
[85.8–95.5]
99.9 (995)
[99.3–100]
n.d. McGiven et al.
(2003)
n.d.
97.6 (636)
[96.0–98.6]
99.9 (1,446)
[99.6–100]
n.d. Nielsen et al. (1995) n.d.
94.5 (147)
[89.2–97.4]
100 (640)
[99.3–100]
n.d. Stack et al. (1999) n.d.
n.d. n.d 49 (56/4)
[34.8–61.8]
Lord and
Cherwonogrodzky
(1992)
n.d.
100 (112)
[95.9–100]
100 (95)
[95.2–100]
48 (40/2
[31.8–63.7]
Dıaz-Aparicio et al.
(1993)
n.d.
iELISA -NH 100 (75)
[93.9–100]
97.7 (130)
[92.9–99.4]
85.2 (61/3)
[73.3–92.6]
Abalos et al. (2000) n.d.
iELISA -S/LPS 97.2 (146)
[92.7–99.1]
97.8 (6,957)
[97.4–98.1]
n.d. McGiven et al.
(2003)
n.d.
100 (424)
[99.0–100]
99.7 (15,715)
[99.6–99.8]
56.3 (261/n.d.)
[50.1–62.4]
Nielsen et al. (1995) n.d.
100
(98–100 [189])
100 (96.7–100
[112])
n.d. Mu~noz et al. (2004) 58.4 (49.2–67.1
[125])
cELISA-S/LPS 95.2 (146)
[90.0–97.9]
99.7 (1,440)
[99.2–99.9]
n.d. McGiven et al.
(2003)
n.d.
100 (636)
[99.3–100]
99.7 (1,446)
[99.2–99.9]
100 (261/n.d.)
[98.2–100]
Nielsen et al. (1995) n.d.
84.4
(78.3–89.4
[180])
100 (95.9–100
[90])
n.d. Mu~noz et al. (2004) 88.8 (81.9.3–
93.7 [125])
FPA 96.6 (146)
[91.8–98.7]
99.1 (1,947)
[98.5–99.4)
n.d. McGiven et al.
(2003)
n.d.
99.3 (1,084)
[98.5–99.7]
100 (23,755)
[99.98–100]
n.d. Nielsen and Gall
(2001)
n.d.
n.d. n.d 99.2 (248/n.d.)
[96.8–99.9]
Nielsen et al. (1998) n.d.
GD-S/LPS n.d. n.d. 81 (56/4)
[67.2–89.3]
Lord and
Cherwonogrodzky
(1992)
n.d.
GD-NH n.d. n.d. 100 (432/6)
[98.9–100]
Lord et al. (1989) n.d.
RID-NH 92.0 (112)
[84.9–96.0]
100 (95)
[95.2–100]
100 (40/2)
[89.1–100]
Dıaz-Aparicio et al.
(1993)
100 (97.1–100
[125])
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Table A.3: Diagnostic performance of serological tests for the diagnosis of B. melitensis infection in
goats (n.d.: not determined)
Reference Test
% DSp (no./age in months/months after Rev 1
vaccination) [95% CI]
%DSe(1)
Brucella
free(1)
Conjunctival Subcutaneous
Stournara et al.
(2007)
RBT 90.3 99.6 100 (48/≤ 3/4) [90.8–100] n.d.
64 (106/≥ 24/4) [54.2–73.1] n.d.
mRBT 97.5 98.1 100 (48/≤ 3/4) [90.8–100] n.d.
47 (106/≥ 24/4) [37.5–57.0] n.d.
CFT 98.7 100 100 (48/≤ 3/4) [90.8–100] n.d.
86.0 (106/≥ 24/4) [77.4–91.6] n.d.
iELISA 97.5 100 100 (48/≤ 3/4) [90.8–100] n.d.
50.0 (106/≥ 24/4) [40.2–59.8] n.d.
cELISA 96.3 99.4 100 (48/≤ 3/4) [90.8–100] n.d.
90 (106/≥ 24/4) [81.8–94.5] n.d.
FPA 97.5 98.9 98 (48/≤ 3/4) [87.5–99.9] n.d.
81 (106/≥ 24/4) [72.1–87.8] n.d.
Salih-Alj Debbarh
et al. (1996)
iELISA CP28 89 100 100(10/3/1) [65.5–100] n.d.
Dıaz-Aparicio et al.
(1994)
RID-NH 93.4 100 100 (11/3/4) [67.9–100] n.d.
90 (10/adults/4) [54.1–99.5] 10/adults/4)
[44.2–96.5]
(1): Taken from the corresponding study.
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